Koa Shoji Holdings Co.,Ltd. (9273.T)
JPY 611.0
(2.0%)
JPY 611.0
(2.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.1 Billion JPY | 6.54% |
| 2022 | 4.79 Billion JPY | 7.66% |
| 2021 | 4.44 Billion JPY | 10.04% |
| 2020 | 4.05 Billion JPY | 38.72% |
| 2019 | 2.97 Billion JPY | 59.53% |
| 2018 | 1.86 Billion JPY | 3.02% |
| 2017 | 1.79 Billion JPY | -6.84% |
| 2016 | 2.15 Billion JPY | -5.59% |
| 2015 | 2.01 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | 1.35 Billion JPY | -1.12% |
| 2023 Q4 | 1 Billion JPY | -25.78% |
| 2023 Q1 | 1.19 Billion JPY | 35.58% |
| 2023 FY | - JPY | 6.54% |
| 2023 Q2 | 1.37 Billion JPY | 15.06% |
| 2022 Q4 | 879.68 Million JPY | -15.32% |
| 2022 FY | - JPY | 7.66% |
| 2022 Q1 | 981.35 Million JPY | 41.03% |
| 2022 Q2 | 1.19 Billion JPY | 22.23% |
| 2022 Q3 | 1.03 Billion JPY | -13.39% |
| 2021 FY | - JPY | 10.04% |
| 2021 Q4 | 695.85 Million JPY | -24.89% |
| 2021 Q3 | 926.49 Million JPY | -27.2% |
| 2021 Q2 | 1.27 Billion JPY | 44.54% |
| 2021 Q1 | 880.44 Million JPY | 0.34% |
| 2020 Q2 | 952 Million JPY | 35.3% |
| 2020 Q1 | 703.6 Million JPY | -16.38% |
| 2020 FY | - JPY | 38.72% |
| 2020 Q4 | 877.5 Million JPY | -2.03% |
| 2020 Q3 | 895.69 Million JPY | -5.91% |
| 2019 Q2 | 794.53 Million JPY | 510.36% |
| 2019 Q4 | 841.47 Million JPY | 34.1% |
| 2019 Q3 | 627.48 Million JPY | -21.03% |
| 2019 FY | - JPY | 59.53% |
| 2019 Q1 | 130.17 Million JPY | -80.49% |
| 2018 Q3 | 253.15 Million JPY | 9.28% |
| 2018 Q1 | 157.85 Million JPY | -60.1% |
| 2018 FY | - JPY | 3.02% |
| 2018 Q4 | 667.1 Million JPY | 163.51% |
| 2018 Q2 | 231.66 Million JPY | 46.76% |
| 2017 FY | - JPY | -6.84% |
| 2017 Q4 | 395.64 Million JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2016 FY | - JPY | -5.59% |
| 2015 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 15.269% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.417% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 101.815% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 97.267% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -793.501% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 85.942% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 58.412% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 95.052% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -294.558% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 72.183% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 43.145% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -39.009% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -263.624% |
| Tsumura & Co. | 30.77 Billion JPY | 83.421% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 72.748% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 3.213% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 85.644% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 25.87% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 70.884% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 50.45% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 236.044% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 32.455% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 814.516% |
| MedRx Co., Ltd | -884.51 Million JPY | 676.772% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 7.851% |
| Solasia Pharma K.K. | -635 Million JPY | 903.408% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 314.903% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 44.323% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 86.164% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 1047.751% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 80.261% |